Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30;13(6):23259671251337093.
doi: 10.1177/23259671251337093. eCollection 2025 Jun.

Transcatheter Arterial Embolization of Abnormal Neovessels for Patellar Tendinopathy: A Safety Evaluation: A Proof-of-Concept Study

Affiliations

Transcatheter Arterial Embolization of Abnormal Neovessels for Patellar Tendinopathy: A Safety Evaluation: A Proof-of-Concept Study

Shohei Inui et al. Orthop J Sports Med. .

Abstract

Background: Patellar tendinopathy (PT) is common among athletes, and the current care is largely palliative.

Purpose: To evaluate the safety of transcatheter arterial embolization (TAE) in patients with PT refractory to nonoperative treatments.

Study design: Case series; Level of evidence, 4.

Methods: This was a multicenter, retrospective study in which recalcitrant PT was treated using TAE. TAE was performed by infusing temporary embolic material through a catheter inserted into the targeted genicular artery. Complications, numeric rating scale (NRS) for pain, Victorian Institute of Sport Assessment for the patella (VISA-P), time to return to training, and ultrasound findings were reported.

Results: Between March 2017 and February 2023, a total of 98 patients with PT underwent TAE. Nine patients were lost to follow-up, and the remaining 89 patients (69 male; mean age, 26.1 ± 11.9 years) were followed up for 1 to 7 years (mean, 31.2 ± 16.1 months) after TAE. No major complications were observed. Mean VISA-P score improved from 24.9 ± 15.3 at baseline to 43.2 ± 21.6, 55.2 ± 22.3, and 67.4 ± 24.7, at 1, 3, and 6 months of follow-up, respectively. Mean NRS for pain improved from 7.6 ± 1.4 at baseline to 4.5 ± 2.3, 3.5 ± 2.4, and 2.7 ± 2.4 at the corresponding time points. VISA-P and NRS scores were 74.6 ± 26.2 and 2.3 ± 2.7, respectively, at the final follow-up. Mean times for return to light and full training were 7.8 ± 8.7 and 14.3 ± 11.5 weeks, respectively. Ultrasound demonstrated decreased patellar tendon thickness (9.5 ± 1.8 mm at baseline vs 6.6 ± 1.3 mm at the final follow-up) without tendon ruptures.

Conclusion: TAE can be considered a safe alternate to existing treatment options for recalcitrant PT. A randomized controlled trial is required to elucidate its efficacy.

Keywords: TAE; jumper’s knee; patellar tendinopathy; transcatheter arterial embolization.

PubMed Disclaimer

Conflict of interest statement

One or more of the authors has declared the following potential conflict of interest or source of funding: Y.O. has received consulting fees from Asahi Intecc Co, Terumo Corporation, Shimadzu Corporation, and Guerbet and is an advisory board member of Clearfynamic Inc and Nextbiomedical Co. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. Ethical approval for this study was obtained from Medical Corporation Yuyu-kai (OC 2024-014).

Figures

Figure 1.
Figure 1.
Fluoroscopic findings in a 19-year-old man with patellar tendinopathy. Digital subtraction angiography from the right inferior genicular artery before (b) and after (c) embolization. Abnormal neovessels (“tumor blush”–type enhancement; black arrowheads, b) disappeared after embolization. Black arrow: catheter tip.
Figure 2.
Figure 2.
Selective angiography in a 21-year-old woman with patellar tendinopathy before and after embolization. Digital subtraction angiography from the right inferior genicular artery before (a-c) and after (d-f) embolization. Abnormal neovessels and early venous return (white arrows, c) disappeared after embolization.
Figure 3.
Figure 3.
Bar graph showing the percentage change in modified Blazina scores before transcatheter arterial embolization (TAE); at 1, 3, and 6 months after TAE; and at the final evaluation.
Figure 4.
Figure 4.
Bar graph showing the mean time from the initial transcatheter arterial embolization to return to full training by sport level. The duration was shortest for professional athletes (8.9 ± 4.7 weeks) and longest for recreational athletes (21.9 ± 16.9 weeks), with significant differences between the 2 groups. C, college athletes; H, high school athletes; P, professional athletes; R, recreational athletes.
Figure 5.
Figure 5.
Ultrasound imaging of patellar tendon before and 1 year after embolization.

References

    1. Alfredson H, Ohberg L, Forsgren S. Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc. 2003;11(5):334-338. - PubMed
    1. Andriolo L, Altamura SA, Reale D, Candrian C, Zaffagnini S, Filardo G. Nonsurgical treatments of patellar tendinopathy: multiple injections of platelet-rich plasma are a suitable option: a systematic review and meta-analysis. Am J Sports Med. 2019;4(4):1001-1018. - PubMed
    1. Aly M, Fashina C, Hagiga A, Hafez A, Di Mascio L. Transcatheter arterial embolization for the relief of shoulder and elbow chronic joint pain refractory to conventional treatment: systematic review. J Med Imaging Radiat Oncol. 2023;67(7):756-768. - PubMed
    1. Bahr R, Fossan B, Løken S, Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (jumper’s knee): a randomized, controlled trial. J Bone Joint Surg Am. 2006;88(8):1689-98. - PubMed
    1. Challoumas D, Pedret C, Biddle M, et al. Management of patellar tendinopathy: a systematic review and network meta-analysis of randomised studies. BMJ Open Sport Exerc Med. 2021;7(4):e001110. - PMC - PubMed

LinkOut - more resources